人胚胎干细胞衍生的心肌细胞、心血管祖细胞和骨髓单核细胞在心脏修复中的比较。

Comparison of Human Embryonic Stem Cell-Derived Cardiomyocytes, Cardiovascular Progenitors, and Bone Marrow Mononuclear Cells for Cardiac Repair.

机构信息

Center for Cardiovascular Biology, University of Washington, Seattle, WA 98109, USA; Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA 98109, USA; Department of Pathology, University of Washington, Seattle, WA 98109, USA; School of Medicine, University of Sydney, Sydney, NSW 2006, Australia; Westmead Millennium Institute for Medical Research, University of Sydney, Sydney, NSW 2145, Australia.

出版信息

Stem Cell Reports. 2015 Nov 10;5(5):753-762. doi: 10.1016/j.stemcr.2015.09.011.

DOI:10.1016/j.stemcr.2015.09.011

PMID:26607951

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4649260/

Abstract

Cardiomyocytes derived from human embryonic stem cells (hESC-CMs) can improve the contractility of injured hearts.We hypothesized that mesodermal cardiovascular progenitors (hESC-CVPs), capable of generating vascular cells in addition to cardiomyocytes, would provide superior repair by contributing to multiple components of myocardium. We performed a head-to-head comparison of hESC-CMs and hESC-CVPs and compared these with the most commonly used clinical cell type, human bone marrow mononuclear cells (hBMMNCs). In a nude rat model of myocardial infarction, hESC-CMs and hESC-CVPs generated comparable grafts. Both similarly improved systolic function and ventricular dilation. Furthermore, only rare human vessels formed from hESC-CVPs. hBM-MNCs attenuated ventricular dilation and enhanced host vascularization without engrafting long-term or improving contractility. Thus, hESC-CMs and CVPs show similar efficacy for cardiac repair, and both are more efficient than hBM-MNCs. However, hESC-CVPs do not form larger grafts or more significant numbers of human vessels in the infarcted heart.

摘要

人胚胎干细胞（hESC-CMs）衍生的心肌细胞可改善受损心脏的收缩性。我们假设中胚层心血管祖细胞（hESC-CVPs）除了能生成心肌细胞外，还能生成血管细胞，通过为心肌的多个组成部分做出贡献，从而提供更好的修复效果。我们对 hESC-CMs 和 hESC-CVPs 进行了头对头的比较，并将其与最常用的临床细胞类型，即人骨髓单核细胞（hBMMNCs）进行了比较。在心肌梗死的裸鼠模型中，hESC-CMs 和 hESC-CVPs 生成了类似的移植物。两者都能改善收缩功能和心室扩张。此外，只有少数来自 hESC-CVPs 的人血管形成。hBM-MNCs 减轻了心室扩张并增强了宿主血管生成，而没有长期植入或改善收缩性。因此，hESC-CMs 和 CVPs 在心脏修复方面具有相似的疗效，并且两者都比 hBM-MNCs 更有效。然而，hESC-CVPs 在梗死心脏中并没有形成更大的移植物或更多的人血管。